Skip to main content
. 2017 Nov 21;34(12):2585–2600. doi: 10.1007/s12325-017-0624-6

Fig. 3.

Fig. 3

Frequency distributions were constructed for the final month 12 cohort of persistent ranibizumab (N = 578) and aflibercept (N = 483) patients. These patients did not discontinue or switch treatment during this 12-month post-index period. As the discontinuation gap was defined in this study as more than 120 days (i.e., 4 months), all patients included in this analysis had a record of receiving at least 4 units